Matt Zeller, Novartis country president for Australia and New Zealand, said, “Over the past 35 years, and looking forward, we will continue to deliver innovative treatments to those with breast cancer. We join the national call for zero deaths from this disease in Australia."
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Nyrada commences recruitment for phase one clinical trial
March 17, 2025 - -
Neurizon Therapeutics updates investors on initiatives to lift clinical hold
March 17, 2025 - - Australian Biotech -
Radiopharm Theranostics says new data confirms positive tumour uptake
March 17, 2025 - - Australian Biotech -
Race secures ethics approval for RC220 Phase 1 solid tumour trial
March 17, 2025 - - Australian Biotech -
TGA approves Novartis therapy for most commonly diagnosed type of early breast cancer
March 17, 2025 - - Latest News -
Doctor group changes position on weight-loss therapies and the PBS
March 17, 2025 - - Latest News -
In 2025, the US is more likely to adopt PBS pricing policies than oppose them
March 17, 2025 - - Latest News